PDS Biotechnology Corporation
PDSB
$1.29
-$0.01-0.77%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -11.48% | -9.67% | -9.99% | -7.61% | 5.05% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -13.70% | -19.19% | -15.62% | -23.50% | -17.65% |
| Operating Income | 13.70% | 19.19% | 15.62% | 23.50% | 17.65% |
| Income Before Tax | 9.09% | 17.13% | 13.23% | 21.23% | 15.49% |
| Income Tax Expenses | -34.58% | -45.02% | 38.18% | 38.18% | 38.18% |
| Earnings from Continuing Operations | 10.02% | 19.12% | 12.42% | 20.76% | 14.82% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 10.02% | 19.12% | 12.42% | 20.76% | 14.82% |
| EBIT | 13.70% | 19.19% | 15.62% | 23.50% | 17.65% |
| EBITDA | 13.73% | 19.22% | 15.65% | 23.53% | 17.64% |
| EPS Basic | 25.13% | 31.60% | 25.38% | 31.43% | 23.90% |
| Normalized Basic EPS | 24.22% | 30.09% | 26.11% | 31.87% | 24.57% |
| EPS Diluted | 25.13% | 31.60% | 25.38% | 31.55% | 24.05% |
| Normalized Diluted EPS | 24.22% | 30.09% | 26.11% | 31.87% | 24.57% |
| Average Basic Shares Outstanding | 19.86% | 18.19% | 17.77% | 15.51% | 12.93% |
| Average Diluted Shares Outstanding | 19.86% | 18.19% | 17.77% | 15.51% | 12.93% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |